Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia.

International Center for Transplantation in Thalassemia and Sickle Cell Anemia-Mediterranean Institute of Hematology, Policlinic of the University of Rome Tor Vergata, Tor Vergata, Italy.
Cold Spring Harbor Perspectives in Medicine (Impact Factor: 7.56). 05/2012; 2(5):a011825. DOI: 10.1101/cshperspect.a011825
Source: PubMed

ABSTRACT The globally widespread single-gene disorders β-thalassemia and sickle cell anemia (SCA) can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). HSCT treatment of thalassemia has substantially improved over the last two decades, with advancements in preventive strategies, control of transplant-related complications, and preparative regimens. A risk class-based transplantation approach results in disease-free survival probabilities of 90%, 84%, and 78% for class 1, 2, and 3 thalassemia patients, respectively. Because of disease advancement, adult thalassemia patients have a higher risk for transplant-related toxicity and a 65% cure rate. Patients without matched donors could benefit from haploidentical mother-to-child transplantation. There is a high cure rate for children with SCA who receive HSCT following myeloablative conditioning protocols. Novel non-myeloablative transplantation protocols could make HSCT available to adult SCA patients who were previously excluded from allogeneic stem cell transplantation.


Available from: Javid Gaziev, Jun 14, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoietic SCT is currently the only curative therapy for a range of benign inherited and acquired primary hematologic disorders in children, including BM failure syndromes and hemoglobinopathies. The preferred HLA-matched sibling donor is available for only about 25% of such children. However, there has been substantial progress over the last four decades in the use of alternative donors for those without a matched sibling-including HLA-matched unrelated donors, HLA-haploidentical related donors and unrelated-donor umbilical cord blood-so that it is now possible to find a donor for almost every child requiring an allograft. Below, we summarize the relative merits and limitations of the different alternative donors for benign hematologic conditions, first generally, and then in relation to specific disorders, and suggest recommendations for selecting such an alternative donor.Bone Marrow Transplantation advance online publication, 9 February 2015; doi:10.1038/bmt.2015.1.
    Bone Marrow Transplantation 02/2015; 50(5). DOI:10.1038/bmt.2015.1 · 3.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: During the last 30 years, in addition to the considerable progress made in control and prevention of thalassemias(3), there have also been major advances in their symptomatic management, at least in wealthier countries where appropriate facilities are available. Remarkable improvements in survival in the severe forms of thalassemia have followed the more judicious use of blood transfusion and, in particular, the ability to manage the iron accumulation resulting from transfusion with its severe and ultimately lethal effects on endocrine and cardiac function.
    Cold Spring Harbor Perspectives in Medicine 06/2013; 3(6). DOI:10.1101/cshperspect.a011767 · 7.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone marrow transplantation performance can be limited by a lack of ideal donors, and the role of alternative donor hematopoietic cell transplantation in thalassemia is not well established. Here we used a new treatment protocol (Pc 26.1) in 16 thalassemia patients to perform BMT using phenotypically HLA-identical or one-antigen mismatched relatives (related donors-RDs). We compared these results with HLA matched sibling (matched sibling donors-MSDs) BMT in 66 patients. The entire RD group and 88% of MSD group had sustained engraftment. Rejection incidence was 0% in the RD and 12% (95% CI, 6-21%) in MSD groups (P = 0.15), with respective thalassemia-free survival (TFS) probabilities of 94% (95% CI, 63-99%) and 82% (95% CI, 70-89%) (P = 0.24). Transplant-related mortality was 6% (95% CI, 1-26%) in the RD group and 8% (95% CI, 3-16%) in the MSD group (P = 0.83). The intensified new protocol was not associated with increased nonhematological toxicity. The present data show that the Pc 26.1 preparative regimen allows thalassemia patients to safely undergo BMT from related donors who are not HLA-matched siblings, with transplant outcomes similar to patients of MSD grafts.
    Blood 08/2013; 122(15). DOI:10.1182/blood-2013-07-513473 · 9.78 Impact Factor